Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > First Patient Dosed in Phase 1 Trial of TH1902

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 24, 2021 9:35am

83 Views

Post# 32865374

RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902

So if they put out that PR Mar 10th then presumably that's when they got their local ethical/legal approval done. Screening, recruitment and dosing took two weeks. Sounds about right.

qwerty22 wrote:

They put out their own PR

https://gettysburgcancercenter.com/a-phase-1-open-label-dose-escalation-study-of-th1902-in-patients-with-advanced-solid-tumors-and-expansion-in-patients-with-triple-negative-breast-cancer-gynecological-cancer-colorectal-cancer-and/

Wino115 wrote: It is rather odd the quote didn't come from MD Anderson, a super-well known global cancer center, and the lead investigator there. Gettysburg, as many know, is a rather tiny town in rural Pennsylvania. Not known as a cancer center! Maybe they are one of the clinics the CMO is working with for the post-escalation phase? But, not a place or doctors that I think would be considered KOLs by anyone.

palinc2000 wrote:
Are those names familiar to us? Are they considered as KoL?
f Dosing the first patient with TH1902 brings us closer to a potential much needed new option in oncology,” said Dr. Satish Shah, Medical Director, Gettysburg Cancer Center, Gettysburg, Pennsylvania and Dr. Tina Khair, Research Director, Gettysburg Cancer Center.

SPCEO1 wrote: I wonder what caused them to say the trial would start in Q2 so recently? And that we would hear safety data in the late summer? I have to think we could be getting info on safety much sooner than that now. Maybe they are learning the beating expectations game a bit better - they now are settling expectations they know they will beat. By doing so, the narrative they create is of a company that is a winner. It may be silly but it works, especially if the drug turns out to be safe and effective. But creating a positive narrative about TH is an important part of getting the stock valued in line with peers.

palinc2000 wrote: Pleasant surprise.....